|
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia Clinical research trials and Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia. Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia clinical trial. Subjects frequently get the best healthcare possible for their Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia  Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
For Condition: refractory chronic myelogenous leukemia,accelerated phase chronic myelogenous leukemia,chronic phase chronic myelogenous leukemia,blastic phase chronic myelogenous leukemia
Status: Completed
Sponsor(s): National Cancer Institute (NCI) , Memorial Sloan-Kettering Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have relapsed or refractory chronic myelogenous leukemia.
Details: OBJECTIVES: I. Determine the antileukemic efficacy of arsenic trioxide in patients with relapsed and/or refractory, chronic, accelerated, or blastic phase chronic myelogenous leukemia. II. Determine the pattern of clinical adverse experience in this patient population administered this drug. PROTOCOL OUTLINE: Patients are stratified according to disease stage (chronic phase vs accelerated phase or blastic phase). Patients receive arsenic trioxide IV over 1 hour on consecutive days or weekdays only for a total of 25 days followed by 3-5 weeks of rest. Treatment continues for a maximum of 6 courses in the absence of unacceptable toxicity or disease progression. Patients with responding disease are followed at least monthly. PROJECTED ACCRUAL: A total of 10-27 patients will be accrued for the chronic phase stratum of this study within 2 years. A total of 17-37 patients will be accrued for the accelerated and blastic phases stratum of this study within 2 years.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: /
Genders:
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Chronic myelogenous leukemia (CML) confirmed by: Cytogenetic testing demonstrating presence of t(9:22) OR RT-PCR demonstrating presence of BCR/ABL rearrangement - Chronic phase; Blast count less than 15% OR Accelerated phase defined by 1 or more of the following: Blast count greater than 15% but less than 30%; Blast count and promyelocytes greater than 30%; Basophils greater than 20%; Thrombocytopenia less than 100,000/mm3 not related to therapy; Cytogenetic clonal evolution (13) OR Blastic phase; Blast count greater than 30% OR Evidence of extramedullary blasts - Relapse from or failure to achieve a major cytogenetic response to at least 1 course of standard anti-CML therapy including interferon alfa or cytotoxic chemotherapy; Must have failed adequate trial of interferon alfa unless intolerance to or contraindication to interferon alfa - Not eligible for allogeneic stem cell transplant --Prior/Concurrent Therapy-- - Biologic therapy: See Disease Characteristics; At least 4 weeks since prior interferon alfa - Chemotherapy: See Disease Characteristics; At least 4 weeks since prior chemotherapy (1 day for hydroxyurea); No other concurrent chemotherapy - Endocrine therapy: Not specified - Radiotherapy: No concurrent radiotherapy - Surgery: Not specified - Other: No other concurrent investigational agents --Patient Characteristics-- - Age: Not specified - Performance status: Karnofsky 70-100% - Life expectancy: Not specified - Hematopoietic: See Disease Characteristics - Hepatic: Bilirubin no greater than 1.5 times upper limit of normal (ULN) - Renal: Creatinine no greater than 1.5 times ULN - Other: Not pregnant or nursing; Negative pregnancy test; Fertile patients must use effective contraception during and for 4 months after study; No active serious infections that are not controlled by antibiotics
Total Enrollment:
Location and Contact Information:
Overall Study Official:
DavidScheinberg, Study Chair, Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
New York City, New York, 10021
United States
Additional Information:
Study ID Numbers: CDR0000067755; MSKCC-99076A,NCI-190
Study Start Date: February 2000
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00005618
Other Chronic Phase Chronic Myelogenous Leukemia Studies:
1. Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia
2. Amifostine and High-Dose Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Chronic Myelogenous Leukemia
3. Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
4. Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia
5. Flavopiridol and Imatinib Mesylate in Treating Patients With Hematologic Cancer
Related Studies:
Other chronic phase chronic myelogenous leukemia Clinical Trials
Other New York Clinical Trials
Other New York City Clinical Trials
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
|
|
|
|
|
|
|
|
